OBJECTIVE: To assess long-term outcomes of children with JIA diagnosed in the biologic era. METHODS: Chart review of patients prospectively enrolled in the Research in Arthritis in Canadian Children Emphasizing Outcomes inception cohort at two Canadian centres. Inactive disease and remission were defined according to Wallace criteria. RESULTS: We included 247 of 254 (97%) eligible patients diagnosed 2005-10. At the last follow-up visit at a median age of 16.9 years, 47% were in remission off medications, 25% in remission on medications and 27% had active disease; 51% were on at least one anti-rheumatic medication (22% on biologics). Patients with systemic JIA had the highest frequency of remission off medications (70%) and patients with RF-positive polyarthritis had the lowest (18%) (P <0.05 by Fisher's exact test). Among 99 patients with oligoarthritis at enrolment, 14 (14%) had an oligoarthritis extended course. Forty-five patients (18%) had at least one erosion or joint space narrowing in X-rays or MRI, and two (0.8%) required joint replacement. CONCLUSION: Relative to historical cohorts, this study suggests a reduction in JIA permanent damage, a more favourable prognosis for systemic JIA and a lower progression to oligoarthritis extended category. However, in an era of biologic therapy, one in four patients with JIA still enter adulthood with active disease and one in two still on treatment.
OBJECTIVE: To assess long-term outcomes of children with JIA diagnosed in the biologic era. METHODS: Chart review of patients prospectively enrolled in the Research in Arthritis in Canadian Children Emphasizing Outcomes inception cohort at two Canadian centres. Inactive disease and remission were defined according to Wallace criteria. RESULTS: We included 247 of 254 (97%) eligible patients diagnosed 2005-10. At the last follow-up visit at a median age of 16.9 years, 47% were in remission off medications, 25% in remission on medications and 27% had active disease; 51% were on at least one anti-rheumatic medication (22% on biologics). Patients with systemic JIA had the highest frequency of remission off medications (70%) and patients with RF-positive polyarthritis had the lowest (18%) (P <0.05 by Fisher's exact test). Among 99 patients with oligoarthritis at enrolment, 14 (14%) had an oligoarthritis extended course. Forty-five patients (18%) had at least one erosion or joint space narrowing in X-rays or MRI, and two (0.8%) required joint replacement. CONCLUSION: Relative to historical cohorts, this study suggests a reduction in JIA permanent damage, a more favourable prognosis for systemic JIA and a lower progression to oligoarthritis extended category. However, in an era of biologic therapy, one in four patients with JIA still enter adulthood with active disease and one in two still on treatment.
Authors: Ellen Nordal; Marek Zak; Kristiina Aalto; Lillemor Berntson; Anders Fasth; Troels Herlin; Pekka Lahdenne; Susan Nielsen; Bjørn Straume; Marite Rygg Journal: Arthritis Rheum Date: 2011-09
Authors: Angelo Ravelli; Alessandro Consolaro; Gerd Horneff; Ronald M Laxer; Daniel J Lovell; Nico M Wulffraat; Jonathan D Akikusa; Sulaiman M Al-Mayouf; Jordi Antón; Tadej Avcin; Roberta A Berard; Michael W Beresford; Ruben Burgos-Vargas; Rolando Cimaz; Fabrizio De Benedetti; Erkan Demirkaya; Dirk Foell; Yasuhiko Itoh; Pekka Lahdenne; Esi M Morgan; Pierre Quartier; Nicolino Ruperto; Ricardo Russo; Claudia Saad-Magalhães; Sujata Sawhney; Christiaan Scott; Susan Shenoi; Joost F Swart; Yosef Uziel; Sebastiaan J Vastert; Josef S Smolen Journal: Ann Rheum Dis Date: 2018-04-11 Impact factor: 19.103
Authors: Mohammad J Al-Matar; Ross E Petty; Lori B Tucker; Peter N Malleson; Maria-Louise Schroeder; David A Cabral Journal: Arthritis Rheum Date: 2002-10
Authors: Carol A Wallace; Edward H Giannini; Bin Huang; Lukasz Itert; Nicolino Ruperto Journal: Arthritis Care Res (Hoboken) Date: 2011-07 Impact factor: 4.794
Authors: N Ruperto; J E Levinson; A Ravelli; E S Shear; B Link Tague; K Murray; A Martini; E H Giannini Journal: J Rheumatol Date: 1997-05 Impact factor: 4.666
Authors: Kiem Oen; Peter N Malleson; David A Cabral; Alan M Rosenberg; Ross E Petty; Mary Cheang Journal: J Rheumatol Date: 2002-09 Impact factor: 4.666
Authors: Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto Journal: Nat Rev Dis Primers Date: 2022-01-27 Impact factor: 65.038
Authors: Thaschawee Arkachaisri; Kai Liang Teh; Yun Xin Book; Sook Fun Hoh; Xiaocong Gao; Lena Das Journal: J Clin Med Date: 2021-02-03 Impact factor: 4.241
Authors: Fernando García-Rodríguez; Augusto Gamboa-Alonso; Sol Jiménez-Hernández; Lucero Ochoa-Alderete; Valeria Alejandra Barrientos-Martínez; Neri Alejandro Alvarez-Villalobos; Gabriela Andrea Luna-Ruíz; Ingris Peláez-Ballestas; Ana Victoria Villarreal-Treviño; Manuel Enrique de la O-Cavazos; Nadina Rubio-Pérez Journal: Pediatr Rheumatol Online J Date: 2021-10-09 Impact factor: 3.054
Authors: Raed M Alzyoud; Motasem O Alsuweiti; Heba Q Almaaitah; Bushra N Aladaileh; Mohammad K Alnoubani; Adel M Alwahadneh Journal: Pediatr Rheumatol Online J Date: 2021-06-12 Impact factor: 3.054